PeptideStack
5.2kquestions
20kanswers
220users

How comparable are orforglipron and semaglutide on the evidence available?

Asked 17 Oct 2025Modified 9 months agoViewed 2.5k times
4

For reference: orforglipron · semaglutide.

Both of these get recommended confidently by different people, which suggests neither is obviously right.

My constraints are cost, measurement resolution and how much handling I am prepared to do — in roughly that order.

Under what conditions does the answer flip?

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questionssemaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questionstirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questionsorforglipron
orforglipron

A non-peptide, orally bioavailable small-molecule GLP-1 receptor agonist studied in the ATTAIN programme. It is not a peptide, which changes…

219 questions
shareeditfollowflag
LF
askedleah_ferrers12k1617 Oct 2025
7Add whether the comparator was placebo or an active agent. – loss_on_drying 6 months ago
6Voting to keep this open — it is more specific than it first looks. – Dr_Yusuf_Adeyemi 5 months ago
add a comment

No answers yet

This question has not been answered. It has been viewed 2.5k times, which suggests the question is of interest and the answer is not obvious. If you can answer it with a source or a worked calculation, it will be read. See how to ask and answer.
Sponsored

Sigma-Aldrich - Certified Reference Materials

Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.

Shop standards

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.